Articles related to Pharmacy & 340B

< back to service

Ninth Circuit Permits 340B-Based FCA Claims to Proceed Despite Lack of Private Right of Action

[03/25/26]

DOL Proposed Rule Would Impose Transparency Requirements on PBMs Providing Services to Self-Insured Health Plans

[02/13/26]

Pressure on PBMs Intensifies as FTC Targets Top PBMs Over Insulin Rebates

[09/30/24]

U.S. Supreme Court Issues Ruling Rejecting Challenge to Mifepristone Access

[06/18/24]

HHS Publishes Its Final 340B ADR Regulation

[04/18/24]

Federal Court of Appeals Panel Issues Ruling in Litigation Challenging FDA Approval of Mifepristone

[08/31/23]

Proposed CMS Rule Targets PBM Price Transparency for Medicaid Managed Care Organizations

[06/23/23]

DEA Proposes New Rules that Would Permanently Allow for Telemedicine Controlled Substance Prescriptions

[02/27/23]

No Surprises Act Enforcement Begins

[02/20/23]

FDA Expands Access to Mifepristone: Next Steps for Providers and Retail Pharmacies

[02/07/23]

FDA Issues Prescription Drug Importation Guidance: Recommendations for Certain Importers of Canadian Drugs

[07/29/22]

FDA Proposes National Licensing Standards for Wholesale Drug Distributors and Third‑Party Logistics Providers

[05/11/22]

PREP Act Liability Coverage Extended to Pharmacists and Interns for Flu Vaccination

[02/04/22]

DEA Soliciting Input for Development of Telepharmacy Practice Regulations

[12/23/21]

PREP Act Eligibility Expanded for Pharmacists, Pharmacy Technicians and Interns Administering COVID-19 Therapeutics

[10/01/21]